Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980239 · ClinicalTrials.gov registry record · Phase 1
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT00980239: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00980239 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00980239, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the highest tolerable dose of irinotecan that can be given directly into the liver, in combination with other drugs given by vein. The other drug combinations given by vein include bevacizumab alone, bevacizumab plus oxaliplatin, and bevacizumab plus cetuximab. This will be tested in patients with advanced solid tumors that have spread to the liver. The safety of these drug combinations will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Oxaliplatin
- DRUG Cetuximab
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980239
The ClinicalTrials.gov registry entry for NCT00980239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00980239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00980239 about?
NCT00980239 is a clinical study titled "HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver". The goal of this clinical research study is to learn the highest tolerable dose of irinotecan that can be given directly into the liver, in combination with other drugs given by vein. The other drug combinations given by vein include bevacizumab alone, bevacizumab plus oxaliplatin, and bevacizumab ...
What is the current status of trial NCT00980239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2009-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00980239?
The interventions under investigation include: Bevacizumab (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00980239?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.